Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.
Am J Cancer Res
; 12(9): 4083-4102, 2022.
Article
en En
| MEDLINE
| ID: mdl-36225648
ABSTRACT
Triple-negative breast cancer (TNBC) is the subtype with the least favourable outcomes in breast cancer. Besides chemotherapy, there is a chronic lack of other effective treatments. Advances in omic technologies have liberated us from the ambiguity of TNBC heterogeneity in terms of cancer cell and immune microenvironment in recent years. This new understanding of TNBC pathology has already led to the exploitation of novel nanoparticulate systems, including tumor vaccines, oncolytic viruses, and antibody derivatives. The revolutionary ideas in the therapeutic landscape provide new opportunities for TNBC patients. Translating these experimental medicines into clinical benefit is both appreciated and challenging. In this review, we describe the prospective nanobiotherapy of TNBC that has been developed to overcome clinical obstacles, and provide our vision for this booming field at the overlap of cancer biotherapy and nanomaterial design.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Am J Cancer Res
Año:
2022
Tipo del documento:
Article
País de afiliación:
China